sintilimab
eli lilly
['mds', 'sintilimab']
sintilimab plus decitabine demonstrates 62% orr in untreated, higher-risk mds #eha22 #oncology #hematology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.